Information for Professional Attendees

September 6 - 9, 2018
Northern Kentucky Convention Center
Cincinnati Marriott at RiverCenter

Click Here to Register

Call for Abstracts

DEADLINE - June 15, 2018

The LAM Foundation and the NCATS/NIH Rare Lung Diseases Consortium hope you will join us for the 2018 International Rare Lung Diseases Research Conference, to be held in Cincinnati, Ohio, on September 6-9, 2018. RLDC·2018 is designed to advance rare lung disease research by fostering scientific communication and collaboration, improving clinician knowledge about new diagnostics and therapeutics, and increasing patient understanding about diseases affecting them. For 2018, the conference theme is “Bringing Cutting Edge Technologies to Rare Lung Disease Research”. 

Submitted abstracts will be reviewed by conference chairs and selected for platform or poster presentations based on scientific merit and alignment with session themes. The objective of the poster session is to provide a state-of-the-art overview of research progress in rare lung diseases including lymphangioleiomyomatosis, pulmonary alveolar proteinosis, Langerhans cell histiocytosis, generalized lymphatic anomalies, Hermansky Pudlak Syndrome, and Alpha-1 antitrypsin deficiency, to name a few. Studies on basic and translational science, and clinical aspects of all rare lung diseases are welcome.

To submit an abstract, visit the UC Abstract Submission Portal at

SUBMISSION: The deadline for ABSTRACTS is midnight EDT on June 15, 2018. You will be asked to include a 300 word abstract, 100 word biography and a photo.

NOTIFICATION of ACCEPTANCE: On or before July 15, 2018.

Please contact Katy Marston at, if you have any questions or problems accessing the grant website.

International Rare Lung Diseases Conference

RLDC · 2018 is an innovative conference that will bring together researchers and clinicians interested in studying rare lung diseases (RLDs) for the purpose of accelerating the advancement of RLD scientific research as well as education of clinicians caring for RLD patients. The theme for this year’s conference is “Bringing Cutting Edge Technologies to Rare Lung Disease Research”.

The objectives of this conference include:

  1. Review recent research advances for rare lung diseases.
  2. Explore cutting-edge concepts related to the diagnosis and treatment of rare lung disease patients.
  3. Provide continuing medical education (CME) credits for physicians caring for rare lung disease patients.
  4. Facilitate the translation of rare lung disease research into clinical practice ‘in real time’.
  5. Learn about emerging technologies that could potentially accelerate advancements in rare lung disease research.
  6. Incorporate the ‘patient voice’ in planning and conducting rare lung disease research.

The RLDC•2018 will offer THREE educational experiences:

International Rare Lung Diseases Conference and Technology Intensives:

Day one (Friday) will include presentations on specific rare lung diseases followed by discussion on the use of new cutting-edge technologies to accelerate the advancement of RLD research. Presentations on the impact of novel technologies on RLDs will be provided to stimulate discussion on the use of these technologies on other RLDs.

Technologies that will be explored throughout the conference will include:

  • Single Cell Analysis
  • Gene Editing
  • Personalized Medicine
  • Innovative Trial Design and Outcome Measures
  • Lung Imaging

Rare Lung Diseases Workshops

Day two (Saturday) will consist of RLD-specific workshops that will focus on how these cutting-edge technologies can be incorporated into each of the specific RLDs represented. Diseases that will be represented in these workshops include lymphangioleiomyomatosis, pulmonary alveolar proteinosis, pulmonary Langerhans cell histiocytosis, sarcoidosis, alpha-1 antitrypsin deficiency, nontuberculous mycobacteria and pulmonary fibrosis. Workshop chairs from each group will present the most promising ideas and propose next steps during a closing plenary.

LAMposium Patient and Family Educational Conference

Patient and family education sessions will run concurrently, with topics that cover a broad range of interests to patients and families affected by rare lung diseases. To encourage communication and collaboration between all conference attendees (researchers, clinicians and patients), all participants will dine together and are welcome to attend all sessions.

Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, RARE Lung Diseases Consortium and The LAM Foundation. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians. 
Designation Statement: The University of Cincinnati designates this live activity for a maximum of 14.5 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
Supported by educational grant(s) from: Insmed Incorporated, Sanofi US, CSL Behring